Brief: Tango Therapeutics Reports Positive TNG462 Clinical Data And Provides Update On PRMT5 Development Program
06/11/2024 12:03
Nov 6 (Reuters) - Tango Therapeutics Inc TNGX.O :
* TANGO THERAPEUTICS REPORTS POSITIVE TNG462 CLINICAL DATA
AND
PROVIDES UPDATE ON PRMT5 DEVELOPMENT PROGRAM
* TANGO THERAPEUTICS INC: TNG462 DEMONSTRATED DURABLE
CLINICAL
ACTIVITY ACROSS MULTIPLE TUMOR TYPES
* TANGO THERAPEUTICS INC: MULTIPLE TNG462 COMBINATION
STUDIES
PLANNED IN 1H 2025
* TANGO THERAPEUTICS INC: TNG908 ENROLLMENT BEING STOPPED TO
FULLY
RESOURCE TNG462 AND TNG456
Source text: ID:nBw9kYhvNa
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,